Q2 2017 13F Holders as of 30 Jun 2017
-
Type / Class
-
Equity / COMMON STOCK
-
Shares outstanding
-
123,180,519
-
Total 13F shares
-
33,945,750
-
Share change
-
+8,695,965
-
Total reported value
-
$93,688,694
-
Put/Call ratio
-
4.5%
-
Price per share
-
$2.76
-
Number of holders
-
67
-
Value change
-
+$24,746,005
-
Number of buys
-
43
-
Number of sells
-
18
Institutional Holders of CATALYST PHARMACEUTICALS, INC. - COMMON STOCK (CPRX) as of Q2 2017
As of 30 Jun 2017,
CATALYST PHARMACEUTICALS, INC. - COMMON STOCK (CPRX) was held by
67 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
33,945,750 shares.
The largest 10 holders included
Broadfin Capital, LLC, BAKER BROS. ADVISORS LP, venBio Select Advisor LLC, BlackRock Inc., VANGUARD GROUP INC, JPMORGAN CHASE & CO, STATE STREET CORP, KENNEDY CAPITAL MANAGEMENT, INC., RENAISSANCE TECHNOLOGIES LLC, and NORTHERN TRUST CORP.
This page lists
67
institutional shareholders reporting positions in this security
for the Q2 2017 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.